Literature DB >> 25332957

Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?

Alessio Amatu1, Katia Bencardino1, Andrea Sartore-Bianchi1, Salvatore Siena1.   

Abstract

Entities:  

Year:  2013        PMID： 25332957      PMCID： PMC4200636          DOI： 10.3978/j.issn.2305-5839.2013.01.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.

Authors:  Raghib Ali; Han-Chong Toh; Whay-Kuang Chia
Journal:  Trials       Date:  2011-12-14       Impact factor: 2.279

2.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

3.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

Authors:  Peter M Rothwell; Michelle Wilson; Carl-Eric Elwin; Bo Norrving; Ale Algra; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-10-21       Impact factor: 79.321

4.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Authors:  Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

Review 5.  Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.

Authors:  Jeffrey S Berger; Anuradha Lala; Mori J Krantz; Gizelle S Baker; William R Hiatt
Journal:  Am Heart J       Date:  2011-07       Impact factor: 4.749

6.  Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Authors:  John C Mathers; Mohammad Movahedi; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diana Eccles; Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm Dunlop; Judy W C Ho; Shirley Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans Vasen; Anne-Marie Gerdes; Gail Barker; Gillian Crawford; Faye Elliott; Kirsi Pylvanainen; Juul Wijnen; Riccardo Fodde; Henry Lynch; D Timothy Bishop; John Burn
Journal:  Lancet Oncol       Date:  2012-11-07       Impact factor: 41.316

7.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

8.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

9.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

Review 10.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Authors:  Peter M Rothwell; Jacqueline F Price; F Gerald R Fowkes; Alberto Zanchetti; Maria Carla Roncaglioni; Gianni Tognoni; Robert Lee; Jill F F Belch; Michelle Wilson; Ziyah Mehta; Tom W Meade
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321
View more
  4 in total

Review 1.  Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies.

Authors:  Jamil Akkad; Sylvia Bochum; Uwe M Martens
Journal:  Langenbecks Arch Surg       Date:  2015-02-10       Impact factor: 3.445

Review 2.  Integration of molecular pathology, epidemiology and social science for global precision medicine.

Authors:  Akihiro Nishi; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Andy S Tan; Ichiro Kawachi; Shuji Ogino
Journal:  Expert Rev Mol Diagn       Date:  2015-12-04       Impact factor: 5.225

Review 3.  Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.

Authors:  Henry T Lynch; Kristen Drescher; Joseph Knezetic; Stephen Lanspa
Journal:  Curr Treat Options Oncol       Date:  2014-09

4.  Simultaneous hepatic resection benefits patients with synchronous colorectal cancer liver metastases.

Authors:  Yuan Li; Xinyu Bi; Jianjun Zhao; Zhen Huang; Jianguo Zhou; Zhiyu Li; Yefan Zhang; Hong Zhao; Jianqiang Cai
Journal:  Chin J Cancer Res       Date:  2016-10       Impact factor: 5.087
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.